AR045671A1 - Moleculas de union de nogo a y su uso farmaceutico - Google Patents
Moleculas de union de nogo a y su uso farmaceuticoInfo
- Publication number
- AR045671A1 AR045671A1 ARP040103334A ARP040103334A AR045671A1 AR 045671 A1 AR045671 A1 AR 045671A1 AR P040103334 A ARP040103334 A AR P040103334A AR P040103334 A ARP040103334 A AR P040103334A AR 045671 A1 AR045671 A1 AR 045671A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding molecule
- seq
- human
- nogo
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Polinucleótido que codifica dicha molécula de unión; un vector de expresión que comprende dicho polinucleótido; un sistema de expresión que comprende un polinucleótido capaz de producir una molécula de unión; una célula huésped aislada que comprende un sistema de expresión como se definió anteriormente; el uso de dicha molécula de unión como un farmacéutico, especialmente en el tratamiento de reparación de nervios; una composición farmacéutica que comprende dicha molécula de unión; y un método para el tratamiento de enfermedades asociadas con la reparación de nervios. Reivindicación 1: Una molécula de unión que es capaz de unirse al polipéptido Nogoa humano (SEC ID NO:%) o NiG humano (SEC ID NO:/) o NiG-D20 humano (SEC ID NO:24) o Nogoa_342-357 humano (SEC ID NO:6) con una constante de disociación <1000 nM.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321997.9A GB0321997D0 (en) | 2003-09-19 | 2003-09-19 | Organic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045671A1 true AR045671A1 (es) | 2005-11-02 |
Family
ID=29266310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103334A AR045671A1 (es) | 2003-09-19 | 2004-09-16 | Moleculas de union de nogo a y su uso farmaceutico |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090181023A1 (es) |
| EP (3) | EP2423225A3 (es) |
| JP (1) | JP2007527232A (es) |
| KR (1) | KR20060119982A (es) |
| CN (1) | CN1878792A (es) |
| AR (1) | AR045671A1 (es) |
| AU (2) | AU2004274164B2 (es) |
| BR (1) | BRPI0414174B8 (es) |
| CA (1) | CA2538725C (es) |
| CO (1) | CO5680457A2 (es) |
| EC (1) | ECSP066431A (es) |
| GB (1) | GB0321997D0 (es) |
| IL (2) | IL174145A (es) |
| IS (1) | IS8404A (es) |
| MA (1) | MA28088A1 (es) |
| MY (2) | MY161068A (es) |
| NO (1) | NO20061678L (es) |
| NZ (1) | NZ545679A (es) |
| PE (1) | PE20050949A1 (es) |
| RU (1) | RU2380377C2 (es) |
| SG (1) | SG146660A1 (es) |
| TN (1) | TNSN06085A1 (es) |
| TW (1) | TWI372060B (es) |
| WO (1) | WO2005028508A2 (es) |
| ZA (1) | ZA200601842B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7988964B2 (en) * | 2003-12-22 | 2011-08-02 | Glaxo Group Limited | NOGO-a neutralising immunoglobulin for treatment of neurological diseases |
| WO2006059959A1 (en) * | 2004-12-01 | 2006-06-08 | National University Of Singapore | Nogo a protein fragments as neuronal network-interacting peptides |
| HRP20120851T1 (hr) * | 2005-07-05 | 2012-11-30 | Glaxo Group Limited | Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| AU2008317724B2 (en) | 2007-11-02 | 2011-06-02 | Novartis Ag | Improved Nogo-A binding molecules and pharmaceutical use thereof |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| IN2014KN02952A (es) | 2012-07-05 | 2015-05-08 | Glaxo Group Ltd | |
| CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
| CN114470197B (zh) * | 2022-02-16 | 2023-10-03 | 天津长和生物技术有限公司 | 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用 |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0383417B1 (en) | 1989-02-13 | 1995-12-27 | Schering Aktiengesellschaft | Vampire bat salivary Plasminogen activator vPA-alpha 1 |
| DE69942803D1 (de) * | 1998-07-22 | 2010-11-11 | Smithkline Beecham Ltd | Rotein änhelt, und dafür kodierende cdns |
| HUP0203863A3 (en) * | 2000-01-12 | 2008-03-28 | Univ Yale | Nogo receptor-mediated blockade of axonal growth |
| AU2002357770B2 (en) * | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| US7988964B2 (en) * | 2003-12-22 | 2011-08-02 | Glaxo Group Limited | NOGO-a neutralising immunoglobulin for treatment of neurological diseases |
-
2003
- 2003-09-19 GB GBGB0321997.9A patent/GB0321997D0/en not_active Ceased
-
2004
- 2004-09-16 AR ARP040103334A patent/AR045671A1/es unknown
- 2004-09-17 CN CNA2004800332675A patent/CN1878792A/zh active Pending
- 2004-09-17 EP EP10176103A patent/EP2423225A3/en not_active Withdrawn
- 2004-09-17 NZ NZ545679A patent/NZ545679A/en not_active IP Right Cessation
- 2004-09-17 EP EP04765380A patent/EP1668033A2/en not_active Withdrawn
- 2004-09-17 US US10/572,434 patent/US20090181023A1/en not_active Abandoned
- 2004-09-17 MY MYPI2013003188A patent/MY161068A/en unknown
- 2004-09-17 EP EP10160905A patent/EP2248827A1/en not_active Withdrawn
- 2004-09-17 RU RU2006112849/13A patent/RU2380377C2/ru active
- 2004-09-17 AU AU2004274164A patent/AU2004274164B2/en not_active Ceased
- 2004-09-17 MY MYPI20043786A patent/MY158078A/en unknown
- 2004-09-17 SG SG200806933-8A patent/SG146660A1/en unknown
- 2004-09-17 JP JP2006526602A patent/JP2007527232A/ja active Pending
- 2004-09-17 WO PCT/EP2004/010489 patent/WO2005028508A2/en not_active Ceased
- 2004-09-17 PE PE2004000908A patent/PE20050949A1/es not_active Application Discontinuation
- 2004-09-17 TW TW093128254A patent/TWI372060B/zh not_active IP Right Cessation
- 2004-09-17 KR KR1020067005424A patent/KR20060119982A/ko not_active Ceased
- 2004-09-17 CA CA2538725A patent/CA2538725C/en not_active Expired - Fee Related
- 2004-09-17 BR BRPI0414174A patent/BRPI0414174B8/pt not_active IP Right Cessation
-
2006
- 2006-03-03 ZA ZA200601842A patent/ZA200601842B/en unknown
- 2006-03-06 IL IL174145A patent/IL174145A/en active IP Right Grant
- 2006-03-17 EC EC2006006431A patent/ECSP066431A/es unknown
- 2006-03-17 TN TNP2006000085A patent/TNSN06085A1/en unknown
- 2006-03-29 CO CO06031001A patent/CO5680457A2/es active IP Right Grant
- 2006-04-07 MA MA28921A patent/MA28088A1/fr unknown
- 2006-04-10 IS IS8404A patent/IS8404A/is unknown
- 2006-04-12 NO NO20061678A patent/NO20061678L/no not_active Application Discontinuation
-
2009
- 2009-01-22 AU AU2009200237A patent/AU2009200237B2/en not_active Ceased
- 2009-12-28 IL IL203007A patent/IL203007A/en active IP Right Grant
-
2010
- 2010-06-16 US US12/816,964 patent/US20110008334A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063829A1 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
| Bab et al. | Osteogenic growth peptide: from concept to drug design | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| CO6470863A2 (es) | Mutantes fgf21 y usos de los mismos | |
| BR0315666A (pt) | Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos | |
| ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
| CL2008001814A1 (es) | Anticuerpos anti-factor de crecimiento 1 y 2 semejantes a insulina (igf-1, igf-2); molecula de adn que los codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
| CL2008001634A1 (es) | Anticuerpo de la region regulatoria negativa anti-notch1 aislado; polinucleotido que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; y su uso para preparar un medicamento para tratar un trastorno asociado con un aumento en la señalizacion o expresion de notch1 en un individuo. | |
| EA201690946A1 (ru) | Мутанты fgf21 и их применение | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| CL2019003406A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| ECSP066431A (es) | Moléculas de unión de nogo-a y uso farmacéutico de las mismas | |
| AR072934A1 (es) | Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismas | |
| MEP56408A (en) | Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes | |
| AR069958A1 (es) | Metodo para producir una proteina heterologa de interes | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| Brennan et al. | Stylopeptide 2, a proline-rich cyclodecapeptide from the sponge Stylotella sp. | |
| AR114444A1 (es) | Método de secuenciación para terapia de células t con car |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |